

## Active substances set

**Search phrase:** midostaurin

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

### Acute myeloid leukemia

#### Midostaurin

Midostaurin is indicated in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation-positive.



**REIMBURSEMENT  
WITH RESTRICTIONS**



**ESMO**